Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score
Related Questions
How will the FDA's review timeline for Cemdisiran affect Regeneron's near‑term valuation?
What is the estimated market size for a subcutaneous Myasthenia Gravis therapy and how might this trial success translate into revenue growth?
How does Cemdisiran's efficacy and dosing schedule compare to existing treatments and pipeline competitors in the MG space?